Table 2.
Features significantly and relevantly altered upon 5-FU treatment of CRC organoids.
| Analytical Mode | No. of Experiments 1 | Mean Mass | Retention Time | Regulation | Annotation | MSI Level 4 |
|---|---|---|---|---|---|---|
| HILIC ESI (+) | 3 | 111.0436 | 3.21 | ↑ | Cytosine 2 | 2 |
| 251.1026 | 2.42 | ↓ | 2′-Deoxyadenosine | 1 | ||
| 257.1022 | 3.21 | ↑ | 2′-O-Methylcytidine | 1 | ||
| 2 | 231.1468 | 5.95 | ↓ | AC 4:0 | 2 | |
| 268.0828 | 4.89 | ↑ | Inosine | 2 | ||
| 281.1115 | 7.90 | ↑ | 1-Methyladenosine | 1 | ||
| 633.4739 | 3.78 | ↓ | LysoPC 26:1 | 2 | ||
| HILIC ESI (−) | 3 | 228.0731 | 2.12 | ↑ | 2′-Deoxyuridine | 2 |
| 264.0507 | 2.12 | ↑ | na 3 | - | ||
| 2 | 536.1892 | 2.17 | ↑ | na | - | |
| RPLC ESI (+) | 2 | 705.5341 | 6.75 | ↓ | PC 30:0 | 2 |
| 729.5347 | 6.48 | ↓ | PC 32:2 | 2 |
1 No. of experiments where the applied criteria for significant and relevant response to 5-FU treatment are met. 2 In-source fragment of 2′-O-methylcytidine. 3 Supposed to be related to uracil due to detection of m/z 111.0211 in the fragment spectra of 264.0507. 4 Assignment level according to the metabolomics standard initiative (MSI) [47]. AC, acylcarnitine; LysoPC, lysophosphatidylcholine; PC, phosphatidylcholine; na, not assigned.